Dexlansoprazole Capsule, Delayed Release
Product Images NDC 71335-3071

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Dexlansoprazole (NDC 71335-3071). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Dexlansoprazole 01)

Chemical structure of dexlansoprazole, the active ingredient in Dexlansoprazole delayed release 30 mg oral capsules by Bryant Ranch Prepack.*

FDA Label Image

Figure 1 (Dexlansoprazole 02)

Pharmacokinetic graph showing plasma concentration (ng/mL) of dexlansoprazole over time (hours) for 30 mg and 60 mg doses. The graph compares plasma levels of delayed-release capsules, illustrating concentration changes up to 24 hours after administration.*

FDA Label Image

Label (Lbl713353071)

Label for Dexlansoprazole Delayed-Release Capsules 30 mg, prescription oral capsules, packaged as 30 capsules. The label shows NDC 71335-3071-1 and states the capsules contain 30 mg of dexlansoprazole as enteric-coated granules. It includes storage instructions, dispenser guidance, a barcode, and notes that it is repackaged by Bryant Ranch Prepack, Inc. and manufactured by TWi Pharmaceuticals, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.